{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05042102",
            "orgStudyIdInfo": {
                "id": "GY0010"
            },
            "secondaryIdInfos": [
                {
                    "id": "5R01AA029075",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/5R01AA029075"
                }
            ],
            "organization": {
                "fullName": "VA Connecticut Healthcare System",
                "class": "FED"
            },
            "briefTitle": "Donepezil and Cognitive Training for Alcohol Use Disorder (AUD)",
            "officialTitle": "The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder",
            "therapeuticArea": [
                "Other"
            ],
            "study": "donepezil-and-cognitive-training-for-alcohol-use-disorder-aud"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-08-08",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-05-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-05-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-09-03",
            "studyFirstSubmitQcDate": "2021-09-03",
            "studyFirstPostDateStruct": {
                "date": "2021-09-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-07",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "VA Connecticut Healthcare System",
                "class": "FED"
            },
            "collaborators": [
                {
                    "name": "Yale University",
                    "class": "OTHER"
                },
                {
                    "name": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of the project is to evaluate whether donepezil + cognitive remediation therapy is superior to placebo in reducing heavy drinking in patients with alcohol use disorder in a double-blind, placebo-controlled trial."
        },
        "conditionsModule": {
            "conditions": [
                "Alcohol Use Disorder"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 160,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Donepezil + Cognitive remediation therapy (CRT)",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.",
                    "interventionNames": [
                        "Combination Product: Donepezil + Cognitive remediation therapy (CRT)"
                    ]
                },
                {
                    "label": "Donepezil + Placebo CRT",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.",
                    "interventionNames": [
                        "Combination Product: Donepezil + Placebo CRT"
                    ]
                },
                {
                    "label": "Placebo medication + Cognitive remediation therapy (CRT)",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.",
                    "interventionNames": [
                        "Combination Product: Placebo medication + Cognitive remediation therapy (CRT)"
                    ]
                },
                {
                    "label": "Placebo medication + Placebo CRT",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.",
                    "interventionNames": [
                        "Combination Product: Placebo medication + Placebo CRT"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "COMBINATION_PRODUCT",
                    "name": "Donepezil + Cognitive remediation therapy (CRT)",
                    "description": "Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.",
                    "armGroupLabels": [
                        "Donepezil + Cognitive remediation therapy (CRT)"
                    ]
                },
                {
                    "type": "COMBINATION_PRODUCT",
                    "name": "Donepezil + Placebo CRT",
                    "description": "Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.",
                    "armGroupLabels": [
                        "Donepezil + Placebo CRT"
                    ]
                },
                {
                    "type": "COMBINATION_PRODUCT",
                    "name": "Placebo medication + Cognitive remediation therapy (CRT)",
                    "description": "Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.",
                    "armGroupLabels": [
                        "Placebo medication + Cognitive remediation therapy (CRT)"
                    ]
                },
                {
                    "type": "COMBINATION_PRODUCT",
                    "name": "Placebo medication + Placebo CRT",
                    "description": "Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.",
                    "armGroupLabels": [
                        "Placebo medication + Placebo CRT"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Heavy drinking days",
                    "description": "Heavy drinking days as measured by weekly Time Line Follow Back (TLFB)",
                    "timeFrame": "13 weeks of active intervention"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Global neurocognitive functioning",
                    "description": "Global neurocognitive functioning on a global index of neurocognitive function",
                    "timeFrame": "At 7 weeks and at 13 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion criteria:\n\n1. Males and females 18-80 years of age\n2. Fluency in English and a 6th grade or higher reading level\n3. Meets the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for a current alcohol use disorder (subjects should have a primary alcohol use disorder \\[AUD\\] diagnosis, but may have concurrent occasional use of other substances)\n4. Last alcohol use and at least one heavy drinking day within the past 30 days\n5. Willingness to attend follow-up assessments at 13 weeks\n6. Willingness to submit to Urine Toxicology screenings\n\nExclusion criteria:\n\n1. Lifetime diagnosis of a psychotic disorder, not induced by drug use\n2. Current treatment with opioids or benzodiazepines, which may affect new learning\n3. Involvement in a legal case that may lead to incarceration during the study period\n4. Residential plans that would interfere with participation\n5. Medical illness that may significantly compromise cognition (e.g., Parkinson's, Alzheimer's, Huntington's chorea, moderate or greater TBI)\n6. An uncorrected sensory impairment (hearing or sight) that would seriously interfere with cognitive training\n7. Pre-morbid intelligence quotient (IQ) estimate below 70\n8. Unstable housing or lack of commitment to staying within a geographic area that would make follow-up unlikely\n9. Unwillingness to provide contact information of someone who can help study staff contact the subjects in the event that study staff are unable to maintain contact directly\n10. Allergy to donepezil\n11. Unstable cardiovascular disease or unstable medical condition-clinically determined by a physician\n12. Imminent suicidal or homicidal risk\n13. Pregnant or nursing women, positive pregnancy test, or inadequate birth control methods in women of childbearing potential",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Gihyun Yoon, MD",
                    "role": "CONTACT",
                    "phone": "203-932-5711",
                    "phoneExt": "7421",
                    "email": "gihyun.yoon@yale.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Gihyun Yoon, MD",
                    "affiliation": "Yale University, VA Connecticut Healthcare System",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "VA Connecticut Healthcare System",
                    "status": "RECRUITING",
                    "city": "West Haven",
                    "state": "Connecticut",
                    "zip": "06516",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Gihyun Yoon, MD",
                            "role": "CONTACT",
                            "phone": "203-932-5711",
                            "phoneExt": "7421",
                            "email": "gihyun.yoon@yale.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.27065,
                        "lon": -72.94705
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000437",
                    "term": "Alcoholism"
                },
                {
                    "id": "D000000428",
                    "term": "Alcohol Drinking"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004327",
                    "term": "Drinking Behavior"
                },
                {
                    "id": "D000019973",
                    "term": "Alcohol-Related Disorders"
                },
                {
                    "id": "D000019966",
                    "term": "Substance-Related Disorders"
                },
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3774",
                    "name": "Alcohol Drinking",
                    "asFound": "Alcohol Use",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3783",
                    "name": "Alcoholism",
                    "asFound": "Alcohol Use Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7502",
                    "name": "Drinking Behavior",
                    "relevance": "LOW"
                },
                {
                    "id": "M21842",
                    "name": "Alcohol-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21837",
                    "name": "Substance-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077265",
                    "term": "Donepezil"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002800",
                    "term": "Cholinesterase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018678",
                    "term": "Cholinergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018697",
                    "term": "Nootropic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3777",
                    "name": "Ethanol",
                    "relevance": "LOW"
                },
                {
                    "id": "M1721",
                    "name": "Donepezil",
                    "asFound": "Prediction",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6040",
                    "name": "Cholinesterase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20758",
                    "name": "Cholinergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20774",
                    "name": "Nootropic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "NootAg",
                    "name": "Nootropic Agents"
                }
            ]
        }
    },
    "hasResults": false
}